We have carried out a series of complementary in vivo and in vitro studies to better understand the metabolism of @entity904 by the prostate gland. Male @entity35 were fed either a control diet sufficient in @entity904 [CON group; 0.8 microg @entity904 equivalents (RE)/g diet] or a CON diet supplemented with the synthetic @entity554 @entity11069 ( @entity11069 ; CON+/-4HPR group; 1,173 )microg of @entity11069 /g diet). After an i.v. injection of a physiological radiolabeled dose of @entity904 , the @entity904 content and radioactivity of plasma and a number of tissues, including the prostate glands, were monitored for time periods ranging between 30 min and 41 days. On the basis of the results of these @entity904 turnover studies, we developed tissue subsystem models to describe @entity904 dynamics in the prostates of both the CON and CON+4HPR groups. There was a gradual decrease in the @entity904 content of the prostates of the @entity11069 -treated group as compared with the control, such that by the end of the study period, the CON+4HPR group averaged 0.166 +/- 0.0827 (mean +/- SD) REs, whereas the CON group was 0.732 +/- 0.190 REs. The fraction of @entity904 exiting the prostate each day was not significantly different in the CON as compared with the CON+4HPR group [0.149 +/- 0.103 versus 0.155 +/- 0.191 h(-1) (mean +/- FSD), respectively]; however, the average amount of @entity904 turning over from the CON+4HPR group prostates (0.0885 /microg/day) was nearly three times less than that of the CON group (0.243 microg/day). To obtain more detailed information on the mechanisms that might be involved in the changes in @entity904 kinetics observed in our in vivo studies, we used both a normal @entity1 prostate cell line (PrEC) and a @entity1 @entity263 cell line (LNCaP) to monitor in vitro @entity904 and @entity11069 dynamics. Cells were treated with @entity11069 for different time periods up to 48 h (PrEC) or 96 h (LNCaP). @entity904 in the media was taken up readily by both PrEC and LNCaP cells, and there was conversion of @entity904 to the major storage esters of @entity904 , @entity6247 and @entity69464 , as well as several minor @entity15994 , in a pattern indicative of normal @entity554 esterification activity. Although @entity11069 was taken up readily and over time accumulated in both cell lines, conversion of @entity11069 to its major metabolite, @entity49210 , as well as several other metabolites of @entity11069 was apparent only in the LNCaP cells. Our findings would suggest that a study design that includes appropriately designed complementary in vivo and in vitro experimental systems represents a useful approach to better understanding possible mechanisms involved in basic @entity554 functioning and interactions in the prostate as well as in other organs and related tissue culture systems.

XXXX metabolism in the prostate: effects of administration of the synthetic @entity554 @entity11069 .

@entity1 :: ('9606', 'Species') :: ['human'] @entity6247 :: ('MESH:C014794', 'Chemical') :: ['retinyl palmitate'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate adenocarcinoma'] @entity15994 :: ('CHEBI:16179', 'Chemical') :: ['retinyl esters'] @entity11069 :: ('MESH:D017313', 'Chemical') :: ['N-(4-hydroxyphenyl)retinamide', '4-HPR'] @entity69464 :: ('MESH:C042811', 'Chemical') :: ['retinyl stearate'] @entity904 :: ('MESH:D014801', 'Chemical') :: ['Retinol', 'vitamin A', 'retinol'] @entity35 :: ('10116', 'Species') :: ['Sprague-Dawley rats'] @entity49210 :: ('MESH:C058346', 'Chemical') :: ['N-[4-methoxyphenyl]retinamide'] @entity554 :: ('CHEBI:26537', 'Chemical') :: ['retinoid']
@entity554 :: (CHEBI:26537,Chemical) :: ['Retinoid']
